Ziopharm Oncology

Description: 

Employs novel cell engineering techniques and multigenic gene programs to develop next-generation patient- and donor-derived adoptive cellular therapies based on designer cytokines, such as genetically modified T cells and NK cells, to target hematologic malignancies and solid tumors as well as graft-versus-host-disease.

Location(s): 
Boston MA
United States